SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a global precision medicine company with mobile solutions for clinical laboratory testing to empower physicians and their patients to take control of their health and wellness, announced today that Paul Sonnier, digital health advocate and social entrepreneur, is joining the company’s Strategic Advisory Board.
“Paul Sonnier’s work complements our vision at Pathway,” said Ardy Arianpour, Pathway Genomics’ Chief Commercial Officer. “We look forward to leveraging Paul’s expertise, relationships, and advice to further accelerate our growth in the digital health arena.”
Mr. Sonnier is globally recognized for his digital health advocacy, including promulgation of a modern definition of digital health that incorporates the impact of both the digital and genetics revolutions on health, healthcare, living, and society. He has adeptly leveraged social media to connect and inform professional stakeholders around the globe, including founding the Digital Health group on LinkedIn, which counts more than 35,000 members from across industries. He is also a major presence on Twitter, where he has over 25,000 followers and is the number one influencer in #DigitalHealth and #WearableTech, tweeting via his handle @Paul_Sonnier.
“I’m incredibly excited to be working with Pathway Genomics, an innovator in the genetic testing space,” said Paul Sonnier. “Their unique products empower patients with vital information about their bodies, allowing them to take charge over their own health as well as improve athletic performance. Combined with their precision medicine offerings, Pathway’s unique and powerful services serve to individualize medical treatment, foster disease prevention, improve disease management, and drive down the costs of healthcare.”
Mr. Sonnier’s past roles include serving as a distinguished member of the World Economic Forum (WEF) Global Agenda Council on Digital Health, judge for the XPRIZE Nokia Sensing XCHALLENGE, and Vice President of Partner Development at the Wireless-Life Science Alliance (WLSA).
About Pathway Genomics Corporation
Since its founding in 2008, Pathway Genomics has rapidly become a leader in the commercial healthcare industry. Pathway Genomics’ success lies in its commitment to deliver innovative healthcare solutions. The company’s program with IBM Watson is the first of its kind. The program is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.
Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve or maintain health and wellness. Pathway Genomics’ testing services cover a variety of conditions, including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications, including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com or follow us on Twitter, LinkedIn, and Facebook.